Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

about

Estrogen treatment for acromegaly.Estrogens and selective estrogen receptor modulators in acromegaly.Effects of fulvestrant on biological activity and Wnt expression in rat GH3 cells.A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression.

P2860

Q34296660-66D70EE9-D1DB-4982-BCF8-9098F68647E5 Q34541969-66E79871-B439-4C9F-822A-2ABB3D5B15C9 Q35157707-C0FA951B-A7DD-4496-B8A3-B5A90436BBE6 Q35620283-99CE3872-33C4-488B-B42D-D1D7E502B84D

P2860

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

Item

http://www.wikidata.org/entity/Q51518444

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

@en

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

@nl

type

Item

label

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

@en

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

@nl

prefLabel

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

@en

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

@nl

P1476

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

@en

P2093

Antoine Bennet

http://www.w3.org/2001/XMLSchema#string

Jean-Christophe Maiza

http://www.w3.org/2001/XMLSchema#string

Maria Matta

http://www.w3.org/2001/XMLSchema#string

Philippe Caron

http://www.w3.org/2001/XMLSchema#string

Stéphane Castillo-Ros

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of a patient- and practice-level colorectal cancer screening intervention in health plan members: design and baseline findings of the CHOICE trial

Acromegaly.

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Growth hormone excess promotes breast cancer chemoresistance.

Raloxifene decreases serum IGF-I in male patients with active acromegaly.

Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly.

The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'.

P2888

s11102-010-0287-7

P304

S23-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11102-010-0287-7

http://www.w3.org/2001/XMLSchema#string

P478

15 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21221819

http://www.w3.org/2001/XMLSchema#string

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

about

P2860

P2860

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P698